TY  - JOUR
A1  - Edelmann, Frank
A1  - Wachter, Rolf
A1  - Düngen, Hans-Dirk
A1  - Störk, Stefan
A1  - Richter, Annette
A1  - Stahrenberg, Raoul
A1  - Neumann, Till
A1  - Lüers, Claus
A1  - Angermann, Christiane E.
A1  - Mehrhof, Felix
A1  - Gelbrich, Götz
A1  - Pieske, Burkert
T1  - Heart failure therapy in diabetic patients-comparison with the recent ESC/EASD guideline
JF  - Cardiovascular Diabetology
N2  - Background: 

To assess heart failure therapies in diabetic patients with preserved as compared to impaired systolic ventricular function. 

Methods: 

3304 patients with heart failure from 9 different studies were included (mean age 63 +/- 14 years); out of these, 711 subjects had preserved left ventricular ejection fraction (>= 50%) and 994 patients in the whole cohort suffered from diabetes.

Results: 

The majority (>90%) of heart failure patients with reduced ejection fraction (SHF) and diabetes were treated with an ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) or with beta-blockers. By contrast, patients with diabetes and preserved ejection fraction (HFNEF) were less likely to receive these substance classes (p < 0.001) and had a worse blood pressure control (p < 0.001). In comparison to patients without diabetes, the probability to receive these therapies was increased in diabetic HFNEF patients (p < 0.001), but not in diabetic SHF patients. Aldosterone receptor blockers were given more often to diabetic patients with reduced ejection fraction (p < 0.001), and the presence and severity of diabetes decreased the probability to receive this substance class, irrespective of renal function. 

Conclusions: 

Diabetic patients with HFNEF received less heart failure medication and showed a poorer control of blood pressure as compared to diabetic patients with SHF. SHF patients with diabetes were less likely to receive aldosterone receptor blocker therapy, irrespective of renal function.
KW  - Preserved Ejection Fraction
KW  - Diastocic Dysfunction
KW  - Myocardial-Infarction
KW  - Hyperkalemia
KW  - Eplerenone
KW  - Mortality
KW  - Predictors
KW  - Framingham
KW  - Morbidity
KW  - Outcomes
Y1  - 2011
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-140397
VL  - 10
IS  - 15
ER  -